Prolonged exposure of chromaffin cells to nitric oxide down-regulates the activity of soluble guanylyl cyclase and corresponding mRNA and protein levels by Ferrero, Rut & Torres, Magdalena
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
BMC Biochemistry
Open Access BMC Biochemistry  2002,  3 x Research article
Prolonged exposure of chromaffin cells to nitric oxide 
down-regulates the activity of soluble guanylyl cyclase and 
corresponding mRNA and protein levels
Rut Ferrero and Magdalena Torres*
Address: Departamento de Bioquímica, Facultad de Veterinaria, Universidad Complutense, 28040-Madrid, Spain
E-mail: Rut Ferrero - rutfb@yahoo.es; Magdalena Torres* - mitorres@vet.ucm.es
*Corresponding author
Abstract
Background: Soluble guanylyl cyclase (sGC) is the main receptor for nitric oxide (NO) when the
latter is produced at low concentrations. This enzyme exists mainly as a heterodimer consisting of
one  and one  subunit and converts GTP to the second intracellular messenger cGMP. In turn,
cGMP plays a key role in regulating several physiological processes in the nervous system. The aim
of the present study was to explore the effects of a NO donor on sGC activity and its protein and
subunit mRNA levels in a neural cell model.
Results: Continuous exposure of bovine adrenal chromaffin cells in culture to the nitric oxide
donor, diethylenetriamine NONOate (DETA/NO), resulted in a lower capacity of the cells to
synthesize cGMP in response to a subsequent NO stimulus. This effect was not prevented by an
increase of intracellular reduced glutathione level. DETA/NO treatment decreased sGC subunit
mRNA and 1 subunit protein levels. Both sGC activity and 1 subunit levels decreased more
rapidly in chromaffin cells exposed to NO than in cells exposed to the protein synthesis inhibitor,
cycloheximide, suggesting that NO decreases 1 subunit stability. The presence of cGMP-
dependent protein kinase (PKG) inhibitors effectively prevented the DETA/NO-induced down
regulation of sGC subunit mRNA and partially inhibited the reduction in 1 subunits.
Conclusions: These results suggest that activation of PKG mediates the drop in sGC subunit
mRNA levels, and that NO down-regulates sGC activity by decreasing subunit mRNA levels
through a cGMP-dependent mechanism, and by reducing 1 subunit stability.
Background
The soluble form of guanylyl cyclase (sGC) is the main re-
ceptor for the signaling agent nitric oxide (·NO) [1,2].
This signaling molecule performs important physiological
and biochemical functions in the cardiovascular, pulmo-
nary and neural systems, activating sGC and thus increas-
ing cGMP levels [3–6]. In certain conditions and disease
states such as hypoxia and hypertension, a disturbance in
sGC levels and/or activity may play a crucial role in the
pathophysiology of these disorders [7–9]. Moreover, de-
sensitization of sGC may also be involved in tolerance to
NO when this compound is used for therapeutic purposes
[10,11].
Purification of mammalian sGC yields a heterodimer
comprised of two subunits  and  of which four types ex-
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ist (1, 2, 1, 2) [12–17]. Structurally, each subunit has
a C-terminal cyclase catalytic domain, a central dimeriza-
tion region and a N-terminal portion. This last portion
constitutes the heme-binding domain and represents the
least conserved region of the protein. Cloning and expres-
sion experiments have demonstrated that both  and 
subunits are required for sGC to be functionally active
[18,19]. In mammalian cells, two different heterodimeric
enzymes, 1/1 and 2/1, have been detected, and al-
though 1 and 2 differ in their primary structure, the two
heterodimers were found to be functionally alike [18,20].
Recently, it has been demonstrated the activation of 2
subunit of sGC by NO and this enzyme has a monomeric
structure [21].
While much has been learned about the regulation of NO
synthase [22,23], there is scare data on sGC regulation, de-
spite its critical role in the actions mediated by endog-
enous or exogenous NO [17,24]. Different reports have
shown a decrease in sGC activity after pre-treatment of tis-
sues or cells with NO-releasing compounds, or a higher
sensitivity of the enzyme when endogenous NO synthesis
is inhibited [10,25,26]. However, the mechanism in-
volved in this phenomenon remains unclear. Redox reac-
tions may be a plausible mechanism for enzyme
desensitization, as several studies have shown that the re-
dox state of the enzyme bound heme and protein thiol
groups has a major role in controlling enzyme activity
[10,27,28]. This activity can also be regulated by a phos-
phorylation/dephosphorylation mechanism [29,30], and
there is emerging evidence that sGC activity is regulated
both at the protein and mRNA levels. Several authors have
reported that treatments, such as forskolin, dibutyryl-
cAMP, 3-isobutyl-methyl xanthine [31,32], endotoxin
and/or IL-1 [33,34], NO donating compounds [11,26]
or nerve growth factor [35] affect sGC mRNA levels in var-
ious cell types.
The NO/cGMP pathway has been established as a major
controller of several physiological functions of the nerv-
ous system [6,36]. Moreover, the effects of NO/cGMP on
neuronal differentiation and survival, and synaptic plas-
ticity suggest that this signal transduction pathway regu-
lates gene expression in the nervous system [37]. Since the
role of sGC in transducing inter- and intracellular signals
conveyed by NO is pivotal, knowledge of the molecular
mechanisms involved in sGC regulation may help our un-
derstanding of the physiological and pathophysiological
significance of this signal transduction pathway in the
nervous system. Compared with findings in vascular tis-
sue, little is known about the effect of prolonged exposure
of neural cells to nitric oxide on subsequent NO stimula-
tion of these cells, and the capacity of this agent to elicit
cGMP increases. The aim of the present study was to estab-
lish whether prolonged treatment of chromaffin cells with
low doses of nitric oxide affects sGC activity in a widely
used bovine neural cell model. The findings presented
suggest that chronic exposure to NO decreases sGC activi-
ty by decreasing the availability of 1 subunit protein lev-
els, and the levels of the mRNAs that encode the 1 and 1
subunits.
Results
Desensitization of soluble guanylyl cyclase in cultured bo-
vine chromaffin cells after prolonged DETA/NO treatment
Our first experiments were designed to determine the ca-
pacity of DEA/NO to increase cGMP in bovine chromaffin
cells in order to select the concentration that produced the
maximal stimulation. Figure 1 shows that DEA/NO effec-
tively increased cGMP in chromaffin cells in a concentra-
tion-dependent manner with a calculated EC50 value of
0.36  0.02 mol/L.
To study the effect of prolonged treatment with NO on
sGC DETA/NO (50 mol/L) was added to the culture me-
dium, and at several time points beginning at 2 hours the
medium was withdrawn and replaced with Locke's solu-
Figure 1
Concentration-dependence curves for DEA/NO-stimulated
cGMP accumulation on chromaffin cells. Cells were incu-
bated for 30 min in Locke's solution containing 0.5 mM
IBMX. Then they were stimulated for 10 min with the indi-
cated DEA/NO concentrations and cGMP measured by radi-
oimmunoassay. Results expressed as pmol /106 cells,
corresponding to the mean  standard error of three exper-
iments performed in triplicate, with different cultures. DEA/
NO was freshly prepared every day in NaOH 0.01 N and its
concentration checked by measuring the absorbance at 250
nm. Data were fit to sigmoidal representation by using
Microcal Origing program.
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Figure 2
Pretreatment of chromaffin cells with DETA/NO causes a time-dependent down-regulation of cGMP accumulation in response
to subsequent NO stimulation (A) or YC-1 stimulation (B) without affecting their viability (C). Bovine chromaffin cells were
pretreated with 50 mol/LDETA/NO for the times indicated. Cells where then incubated with 0.5 mmol/L IBMX for 30 min
and stimulated with 1 mol/L DEA/NO or 250 mol/L YC-1 for 10 min. cGMP was determined by radioimmunoassay as
described in Methods. 1C. Cells were incubated with 50 mol/L DETA/NO for 48 hours and then incubated for 30 min in
Locke's solution in the presence of the viability/cytotoxicity probes EthD-1 and calcein-AM. Images were taken under a fluores-
cence microscope using an excitation optical filter and two different emission filters: a 530 nm bandpass filter for calcein (upper
panels) and a 590 nm longpass filter for EthD-1 (lower panels).
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tion containing 0.5 mmol/L of the nonselective phos-
phodiesterase inhibitor IBMX. After 30 min of incubation,
the cells were stimulated with 1 mol/L DEA/NO or 250
mol/L YC-1 for 10 min and the intracellular cGMP con-
tent determined. As illustrated in Fig. 2, exposure to
DETA/NO resulted in a significant time-dependent de-
crease in DEA/NO- or YC-1-stimulted cGMP production
by the chromaffin cells. Maximal reduction was achieved
after 24–48 hours of treatment. Exposure of the chromaf-
fin cells for 24 or 48 hours to 50 mol/L DEATA/NO in-
duced no cell toxicity. The percentage of cells that failed to
exclude EthD-1 did not differ in chromaffin cells incubat-
ed in the presence or absence of DETA/NO. Neither was a
difference noted in the fluorescence due to calcein, an in-
dicator of living cells (Fig. 2C).
Prolonged exposure to NO might alter the intracellular re-
dox state of these cells and sGC contains critical thiol
groups in its catalytic site that are sensitive to oxidative in-
activation. Reduced glutathione (GSH) is the major intra-
cellular redox buffer in most cell types. To determine
whether the reduction in sGC activity caused by NO treat-
ment could be attributed to a drop in reduced intracellular
glutathione, a permeable, reduced glutathione (GSH-ME)
was added simultaneously with the DETA/NO. As shown
in Fig. 3, the amount of cGMP elicited by DEA/NO in cells
treated with GSH-ME was similar to that produced in con-
trol cells. Moreover, in cells treated with DETA/NO, the
presence of this compound neither modified subsequent
DEA/NO stimulation. This indicates that the effect of
DETA/NO may not be ascribed to a decrease in intracellu-
lar sulfhydryl groups. However, when GSH synthesis was
blocked by the addition of 0.5 mmol/L BSO, both DETA/
NO-treated and untreated cells showed a clear reduction
in the DEA/NO-stimulated cGMP increases (about 35%
or 42% respectively).
DETA/NO treatment reduces sGC 1 subunit protein levels
Western blot experiments were performed to establish
whether the depressed sGC activity in cells treated with
DETA/NO could be due to changes in protein levels. Fig-
ure 4A shows a western blot incubated with anti-sGC an-
tibody. This antibody recognized two bands in
chromaffin cell extracts, a significant band at ~78–80 kDa
was consistently present together with a weaker band at
70 kDa. The immunodetection of these bands was specif-
ically prevented by the presence of the corresponding im-
munizing peptide (1 or 1). According to these results
these two bands likely corresponded to the 1 and 1 sub-
units of sGC, although nonspecific binding of the anti-
body would not be discard. As shown in Fig. 4B, treatment
with DETA/NO caused a time-dependent decrease in the
amount of sGC 1 subunit. While in some experiments it
was also possible to detect a decrease in the quantity of 1
subunit at the longest exposure time, the fall in 1 subunit
level was not always evident. Thus, taking together the re-
sults of all the experiments the changes in 1 subunit were
not significantly different. The possibility that the ob-
served reduction in sGC protein levels might be attributa-
ble to differences in the amounts of proteins loaded was
ruled out, since the loading control -actin, remained un-
changed in the different cell extracts. The fall in the
amount of subunit 1 was not prevented by the presence
of the protein synthesis inhibitor cycloheximide indicat-
ing that protein synthesis is not required for the sGC 1
subunit decrease induced by DETA/NO. On the contrary,
Figure 3
Effect of intracellular levels of reduced glutathione (GSH) on
basal (A) or NO-stimulated (B) cGMP accumulation in con-
trol or DETA/NO pretreated cells. Cells were incubated
with the membrane permeable reduced glutathione (GSH-
ME) (2 mmol/L) or with 0.5 mmol/L buthionine-(S,R)-sulfox-
imine (BSO) for 48 hours in the presence or absence of 50
mol/L DETA/NO. The cells were then incubated for 30 min
with 0.5 mmol/L IBMX and basal cGMP levels (A), or DEA/
NO-stimulated cGMP levels (B) determined by radioimmu-
noassay. Significant differences from values obtained in
DETA/NO-untreated cells (empty column) are marked: ***p
< 0.001; **p < 0.01; *p < 0.05 (Paired student's t test). Signifi-
cant differences from values obtained in control cells are
marked: +p < 0.05 (Paired student's t test).
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Figure 4
DETA/NO pretreatment decreases sGC subunit protein levels in bovine chromaffin cells. A.- Immunodetection of sGC in sol-
uble extracts from bovine chromaffin cells. Twenty micrograms of protein and 5 L of molecular weight markers (prestained
precision protein standards from BIO RAD) were electrophoresed and transferred to PVDF membranes and then sGC was
detected by using 1 g/mL of anti-sGC antibody or the antibody plus 80 ng/mL peptide 1 or antibody plus 60 ng/mL peptide
1.) B.- Cells were incubated with 50 mol/L DETA/NO for the times indicated (0, 2, 4, 8, 24, 48 and 72 hours). Cells were
then lysed and equal amounts of proteins (30 g) corresponding to the soluble fraction of cell extracts fractionated by SDS-
PAGE and transferred to PVDF membranes. The two sGC subunits (1 and 1) were immunodetected using a polyclonal anti-
body as described in Methods. a-Actin was immunodetected to check for consistency in loading and transfer.
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as shown in Figure 5B, simultaneous treatment with
DETA/NO and cycloheximide reduced the 1 subunit lev-
el drastically making it practically undetectable in our ex-
perimental conditions.
Decreased steady-state protein levels can be the result of
inhibited protein synthesis or of a decrease in the half-life
of a protein. The amount of cGMP produced in response
to NO was determined in cells treated with DETA/NO for
different lengths of time (Fig. 5A). Since these determina-
tions were performed in the presence of a broad-spectrum
phosphodiesterase inhibitor the variation in NO-stimu-
lated cGMP might reflect changes in sGC activity. A half-
life of 30.6  1 hour was calculated for sGC activity in cells
pretreated with DETA/NO. In the presence of the protein
synthesis inhibitor (cycloheximide), the estimated half-
Figure 5
The half-life of sGC activity was diminished in DETA/NO treated cells. (A) Chromaffin cells were incubated for different times
(0, 4, 8,16, 24,32 and 48 hours) with either 10 mol/L cycloheximide (), 50 mol/L DETA/NO () or with both drugs (▲ ).
Cells were then washed preincubated with 0.5 mmol/L IBMX for 30 min and stimulated with 1 mol/L DEA/NO for 10 min and
cGMP levels determined by radioimmunoassay. Data of DEA/NO-stimulated cGMP levels as a time function are represented in
a linear model according to the equation logA = k.t/2.3 + logA0, where A is the DEA/NO-stimulated cGMP level at each
time and A0 is the DEA/NO-stimulated cGMP level in control cells. From the slopes, the "k " and half-life (t1/2) of sGC activity
in each condition can be calculated according to the expression t1/2 = 2.3 log2/k. (B) Immunoblotting analysis of sGC subunits
(1 and 1) or -actin. Cells were pretreated with either: vehicle (control), 10 mol/L cycloheximide (CHX), 50 mol/L
DETA/NO, or both compounds together. Proteins (30 g) from each group were subjected to electrophoresis and transferred
to PVDF membranes. The membranes were processed as described in Fig. 3. (C) Cell viability after different treatment. Cells
were incubated for 48 hours with either: vehicle (control), 50 mol/L DETA/NO, 10 mol/L cycloheximide or 50 mol/L
DETA/NO plus10 mol/L cycloheximide. After that cells were washed and their viability analyzed as described in Methods.
The values are given as the percentage of live cells and are the mean  SE of three experiments performed in triplicate.
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life was 55  3.6 hours and in the combined presence of
DETA/NO and cycloheximide this value dropped to 23.4
 1.6 hours. This capacity of DETA/NO to induce an even
greater reduction in sGC activity when protein synthesis
was blocked by cycloheximide indicates that DETA/NO
decreases the stability of sGC via a mechanism that is in-
dependent of protein synthesis. The reduction in the
cGMP increased elicited by NO stimulation may not be
explained by a cytotoxic effect of these treatments because
as shown in Fig. 5C they did not modify the number of
live cells.
To explore the mechanisms responsible for the effect of
NO on sGC 1 subunit levels, chromaffin cells were treat-
ed with 10 mol/L ODQ, an inhibitor of sGC, or with 15
mol/L Rp-8-Br-PET-cGMPS, an inhibitor of PKG, 30 min
before exposure to DETA/NO. Inhibition of sGC by ODQ
did not prevent the DETA/NO-induced decrease in 1 sub-
unit levels (Fig. 6). However, in the presence of ODQ
alone, the 1 subunit of sGC showed a similar drop in lev-
el to that shown by cells incubated with DETA/NO or
DETA/NO plus ODQ. Moreover, the presence of a PKG in-
hibitor partially prevented the 1 subunit down regula-
tion caused by DETA/NO. These results suggest the
involvement of PKG activation in the mechanism under-
lying the decrease in sGC 1 subunit levels observed when
cells are chronically exposed to NO. To verify that inhibi-
tion of the effects of DETA/NO was not caused by the pres-
ence of the cGMP analog rather than PKG inhibition,
another cGMP analog and PKG activator, Sp-8-Br-PET-
cGMPS, was added to the cell culture. This compound
failed to prevent the DETA/NO-mediated effect.
DETA/NO treatment causes a drop in mRNA levels corre-
sponding to sGC subunits 1 and 1
The effect of prolonged exposure to NO on the mRNA lev-
els of both the 1 and 1 subunits of sGC was investigated
using a quantitative RT-PCR technique. Fig. 7A presents a
representative agarose gel showing the amplified PCR
products obtained with the primers designed for the 1
and 1 subunits of sGC and the commercial primers for
the 18S rRNA. Each specific primer was used to amplify
single 350, 450 and 300 pb fragments. Quantitative PCR
experiments revealed that treatment of chromaffin cells
with 50 mol/L DETA/NO for 16 hours leads to a reduc-
tion in the mRNAs that code for both sGC subunits (Fig.
7B and 7C). The presence of two PKG inhibitors (Rp-8-Br-
PET-cGMPS and KT5823 at concentrations that only in-
hibited PKG activity in "in vitro" experiments) effectively
abolished the effect of DETA/NO. In cells pretreated with
1 mol/L KT5823, the DETA/NO-induced effect was total-
ly prevented and levels of 1 and 1 subunit mRNAs were
higher than in control cells. The application of Rp-PET-8-
Br-cGMPS at three concentrations had a biphasic effect: at
a concentration of 3 mol/L, it effectively blocked the
DETA/NO response and increased the levels of the two
mRNAs by 1.5 fold with respect to control cells; yet as the
concentration of the PKG inhibitor was increased, the
blocking effect was still produced but the increases pro-
duced in mRNA levels were smaller. At the highest con-
centration tested (30 mol/L), blockage of the response to
DETA/NO was incomplete; 1 and 1 mRNA levels were
80 and 90% of control levels respectively. Addition of the
PKA inhibitor, H-89, at a concentration that selectively in-
hibits this protein kinase, without affecting others, was
unable to prevent the down-regulation of mRNA caused
by DETA/NO treatment. These results might suggest the
involvement of PKG in DETA/NO-induces down-regula-
tion of sGC subunits mRNAs. Additional experiments
where performed in order to discard a possible cross-talk
activation of PKA involved in this mechanism. As shown
in Fig. 8 the amount of 1 and 1 mRNAs was increased
1.6 and 1.9 fold, respectively when cells were incubated
with the cAMP analogue Sp-cAMPS-AM. This effect was ef-
fectively counteracted by co-treatment with H-89. Moreo-
ver H-89 alone was able to decrease the 1 and 1 mRNAs
as compared to control indicating that tonic activity of
PKA is necessary to keep the levels of these mRNAs bal-
anced. Nevertheless the cGMP analogue Sp-PET-8Br-
cGMPS mimicked the effect observed with DETA/NO and
caused a reduction of 40% of both mRNAs supporting the
idea that PKG activation down-regulates the mRNAs en-
coding for sGC subunits (1 and 1).
Discussion
Prolonged treatment of chromaffin cells with DETA/NO
led to desensitization of sGC to subsequent NO or YC-1
stimulation. This depressed sGC activity was accompa-
nied by a decrease in sGC protein levels, involving dimin-
ished levels of the 1 subunit and the mRNAs that code for
the 1 and 1 subunits.
It has been previously described that prolonged treatment
with NO causes a reduction in the intracellular levels of re-
duced thiols and that this can lead to the inactivation of
several proteins [10,38]. However, when the permeable,
reduced glutathione was added to the culture medium,
the effect of DETA/NO on sGC activity was not prevented.
This indicates that the intracellular levels of reduced glu-
tathione in these cells were not likely to be affected by the
concentration of NO employed in the present study,
which is ten times lower than that used in other studies
[38]. However, intracellular levels of reduced glutathione
clearly affect sGC activity, because when cells were deplet-
ed of the GSH by treatment with an inhibitor of its synthe-
sis (BSO), the NO-stimulated cGMP increase was
significantly diminished both in cells treated with BSO
alone and in cells treated with DETA/NO plus BSO, com-
pared to their respective controls. The participation of sev-
eral thiol groups in sGC activity has been described inBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/26
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several reports [39–41]. The thiol groups of cysteine resi-
dues are particular important for the structural and func-
tional properties of proteins. Reducing conditions in the
intracellular environment generally prevent the oxidation
of sulfhydryl groups, and site-directed mutagenesis exper-
iments have shown that the 1 subunit has two cysteine
residues (Cys-78 and Cys 214) required for heme binding
and thus for NO sensitivity [39]. Moreover, the catalytic
site of guanylyl cyclase contains critical thiol groups in-
volved in its activation by NO [41] that are sensitive to ox-
idative inactivation [10,27,28]. In this way, it has been
demonstrated that NO activation of sGC leads to disulfide
formation, which reversibly inactivates the enzyme [28].
In agreement with previous findings, we observed that
prolonged treatment of chromaffin cells with NO leads to
a reduction in the amount of sGC subunit 1. In contrast
the amount of the protein identified as the 1 was not
modified in our experimental conditions. This apparent
discrepancy could be explained by a mistaken identity of
the 1 subunit due to a nonspecific binding of the anti-
body to a protein distinct from this subunit although its
detection was almost completely avoided by the presence
of the 1 peptide used as antigen. On the other hand in
the present work as well as in previous work [29] we have
shown an apparent molecular weight for the large sGC
subunit of 80 kDa. This value is higher to that previously
Figure 6
Inhibition of PKG partially prevents the DETA/NO-induced down-regulation of 1 subunit protein levels. Cells were incubated
with either: vehicle (control), 50 mol/L DETA/NO, 10 mol/L ODQ, 10 mol/L ODQ plus 50 mol/L DETA/NO, 15 mol/L
Rp-8-BrPET-cGMPS (Rp-PET), 15 mol/L Rp-8-BrPET-cGMPS (Rp-PET) plus 50 mol/L DETA/NO, or 10 mol/L Sp-8-BrPET-
cGMPS (Sp-PET) plus 50 mol/L DETA/NO for 48 hours. ODQ, Rp-PET and Sp-PET were added 30 min before DETA/NO.
Proteins (30 g) from each group were subjected to electrophoresis and blotting. sGC was immunodetected and the band cor-
responding to the 1 subunit quantified. Results are expressed as the percentage (%) of the amount of 1 subunit in cells sub-
jected to different treatment with respect to the amount in untreated cells. The figure shows the results given as mean  SE of
five experiments performed with different cultures. Significant differences compared with non-treated cells (control) is indi-
cated by ***p < 0.001 (Student's t test). ++p < 0.01 represents significant difference between DETA/NO-treated cells and
DETA/NO plus Rp-PET-treated cells.
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Figure 7
DETA/NO treatment causes down regulation of mRNAs coding for the 1 and 1 subunits of sGC. PKG inhibitors prevent this
effect. (A) Gel showing the analysis of RT-PCR products for the 1- and 1-subunits of sGC and for 18S ribosomal RNA (used
as internal control) by agarose gel electrophoresis stained with SYBR gold. Total RNA (200 ng) was reverse transcribed and
amplified for 40 cycles. A marker (M) consisting of DNA fragments in increments of 100 bp (lower band, 100 bp) was used to
estimate the size of the PCR products. (B and C) Variation in mRNA content for sGC 1 and 1 mRNAs in cells subjected to
different treatments. Chromaffin cells were incubated with a vehicle (control), or 50 mol/L DETA/NO alone or in the pres-
ence of the PKG inhibitor Rp-8-BrPET-cGMPS at the concentrations 3 mol/L, 15 mol/L or 30 mol/L or 1 mol/L KT5823,
or in the presence of a PKA inhibitor (1 mol/L H89). The protein kinase inhibitors were added 30 min before the DETA/NO.
After 16 hours treatment, total RNA was isolated and used for quantitative RT-PCR using specific primers designed for
mRNAs encoding bovine sGC 1 and 1 subunits. The figure shows the results of four experiments performed in triplicate
given as mean  SE. Significant differences from control are indicated by **p < 0.01; *p < 0.05 (Student's t test). ++p < 0.01;+p <
0.05 (Student's t test) indicates significant differences between cells treated with DETA/NO alone or with DETA/NO plus PKG
inhibitors.
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Figure 8
cAMP up-regulates 1 and 1 sGC mRNAs in bovine chromaffin cells. Cells were incubated during 24 hours with either: vehi-
cle (control), 100 mol/L Sp-cAMPS-AM, 100 mol/L Sp-cAMPS-AM plus 1 mol/L H-89 (this compound was added 30 min
before the addition of cAMP analogue), 1 mol/L H-89, or 30 mol/L Sp-PET-8Br-cGMPS. After treatment, total RNA was iso-
lated and used for quantitative RT-PCR using specific primers designed for 1 (A) and 1 (B) subunits. Results are expressed as
mean  SE of two experiments performed in triplicate. Significant differences from control are indicated by *p < 0.05, **p <
0.01. ++p < 0.01 indicates significant differences between cells treated with Sp-cAMPS-AM and cells treated with Sp-cAMPS-AM
plus H-89.
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reported by Humbert et al (1990) [42]. The discrepancy
between the present and formerly reported molecular
weight of the sGC 1 subunit might be explained by the
existence of different gene products with specific tissue
distribution, because alternative splicing for the 1 subu-
nit has been demonstrated [43]. The time-course experi-
ments revealed a maximal effect on 1 subunit levels after
24 or 48 hours of treatment. Nitric oxide appears to de-
crease the levels of this subunit via a translation-inde-
pendent mechanism. This conclusion is based on the
observation that 1 subunit levels decreased more rapidly
in chromaffin cells exposed to NO than in those exposed
to cycloheximide. Moreover, pretreatment of chromaffin
cells with cycloheximide did not impede NO altering sGC
1 subunit levels; on the contrary, a greater decrease was
recorded. These results are in clear contrast with several re-
ports showing a transduction- and translation-dependent
mechanism involved in the sGC down-regulation caused
by NO [11]. A long half-life has been proposed for sGC in
physiological conditions. We established a half-life of 55
hours for sGC activity by inhibiting protein synthesis in
the present model. It should be noted that the 1subunit
levels but not those of the 1 subunit were reduced in ex-
tracts from cells treated for 48 hours with cycloheximide,
indicating that the estimated half-life reflects that of the 1
subunit. Further, the half-life estimated for the 1 subunit
in extracts of DETA/NO-treated cells, correlates well with
the sGC activity calculated for DETA/NO-treated cells (re-
sults not shown). In contrast, whereas NO treatment de-
creased sGC 1 and 1 subunit mRNA levels, the decrease
at the protein level only occurred in the 1 subunit. This
finding might reflect a higher stability of the 1 subunit
than its counterpart, as previously suggested [31], at least
during continuous exposure to NO. The drop in 1 subu-
nit levels triggered by NO treatment might be the result of
a dual action of NO; decreasing the levels of mRNA that
encode the 1 subunit, on the one hand, and destabilizing
the subunit protein making it more susceptible to proteo-
lytic cleavage, on the other. Destabilization may occur
through nitrosylation of cysteine or tyrosine residues, but
also, prolonged exposure to NO could trigger oxidation of
the ferrous component of the heme group and oxidation
of different residues, mostly cysteine residues. Any of
these modifications could induce conformational chang-
es in the sGC structure making it unstable, although the
fact that ODQ treatment also led to a decrease in 1 sub-
unit levels suggests that oxidation might be the most plau-
sible mechanism. Indeed, it has been demonstrated that
ODQ inhibits sGC activity by oxidation of the iron atom
of the heme group, which changes from the ferrous to the
ferric state [44]. This oxidation leads to heme removal
from sGC and thus the enzyme loses its sensitivity to-
wards NO. The long-term effect of ODQ has not been ex-
plored to date, but it is known to oxidize different
molecules, including sGC. Although this is not likely to be
an exclusive mechanism for regulating sGC, it is clear that
this enzyme is very sensitive to oxidizing environments
[10]. Consistent with this observation is the fact that the
antioxidant, vitamin E, attenuates vascular superoxide an-
ion formation and increases sGC 1-subunit levels in rat
aortic tissue [45].
The observed effect of NO on mRNA levels and its partial
effect on protein levels was mediated by a cGMP and PKG-
dependent mechanism. Two different specific and selec-
tive PKG inhibitors, at a concentration that affected no
other protein kinase at least in "in vitro "experiments,
were able to abolish the effect of NO on the expression of
the sGC subunit gene. Other investigators have also sug-
gested that cGMP regulates sGC subunit gene expression.
Ujiie et al. [26] observed that incubation of cultured rat
medullary interstitial cells with SNP decreased sGC a1 and
1 subunit mRNA levels. Papapetropoulos et al. [10] also
observed a reduction in sGC subunit gene expression after
incubation of aortic smooth muscle cells with zaprinast,
an inhibitor of cGMP degradation by type V phosphodi-
esterase. Similarly, Filippov et al. [11] reported decreased
levels of mRNAs encoding sGC subunits in rat pulmonary
artery smooth muscle cells after NO or 8-Br-cGMP treat-
ment and suggested the involvement of PKG in the under-
lying mechanism. Here, we showed that the PKG
inhibitor, Rp-8-Br-PET-cGMP, was able to attenuate the
ability of NO to alter sGC 1 subunit levels and to fully in-
hibit its effect on sGC subunit gene expression. At low
concentrations, Rp-8-Br-PET-cGMPS also increased sGC
1 and 1 mRNA levels. The same effect was observed
with 1 mol/L KT5823. Several reports have shown that
cAMP-increasing compounds and activation of PKA leads
to a down-regulation of sGC in smooth muscle cells
[31,32]. In addition, the activation of tyrosine kinases
down-regulates sGC levels in PC12 cells [35]. In the
present model, the PKA inhibitor (H-89 at 1 M) was not
able to prevent the DETA/NO effect on sGC mRNA levels.
On the contrary, this compound caused reduction of the
levels of the two mRNAs and counteracted the effect of the
cAMP analogue. These findings could indicate that PKA
positively modulates mRNA levels of the sGC subunits in
these cells and similarly explain the observed biphasic ef-
fect of Rp-8-Br-PET-cGMPS (this compound also inhibits
PKA with a Ki of 11 mol/L). At 30 mol/L in theory PKG
should be inhibited by 95% and PKA by around 50%.
These results clearly contrast with previous findings show-
ing that PKA negatively modulates sGC levels in smooth
muscle cells [31,32]. PKG I expression is also suppressed
by continuous exposure to nitrovasodilators, theophyl-
line, cGMP and cAMP in smooth muscle cells [46], and ac-
tivation of either PKG or PKA leads to a similar
physiological response in this model. Thus, it is conceiva-
ble that if PKG levels fall, PKA activation is the down-
stream element in the regulatory mechanism triggered byBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/26
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NO [47]. In chromaffin cells, however, these two kinases
have opposite effects [48] and PKG levels remaining un-
changed in DETA/NO exposed cells.
Conclusions
In conclusion, exposure of chromaffin cells to low con-
centrations of NO leads to reduced cGMP accumulation
in response to subsequent exposure to NO. The observa-
tion that sGC activity is highly sensitive to conditions of
prolonged exposure to NO may have significant implica-
tions in neural disorders, such as brain trauma or
ischemia, where NOSII is induced and there is a continu-
ous production of NO. While further work is needed to
evaluate the extent to which the decrease in sGC level and
activity contributes to the pathophysiological response, it
may be speculated that a significant reduction in sGC
would affect all cGMP-mediated processes.
Methods
Materials
IBMX, BSO and anti--actin (20–33) were purchased
from Sigma Chemical Co. (St. Louis, MO, USA.). KT-5823
and H-89 were from Calbiochem (San Diego, CA, USA).
DETA/NO, DEA/NO, rabbit anti-GC (soluble) and guan-
ylate cyclase (soluble) blocking peptide were provided by
Cayman Chemical (Ann Arbor, MI, USA). YC-1 was ob-
tained from Alexis Corporation (San Diego, CA, USA.)
and dissolved in DMSO. ODQ was from Tocris Cookson
(Langford, Bristol, U.K.). Adenosine-3',5'-monophospho-
rothioate, Sp-isomer; acetoxymethyl ester (Sp-cAMPS-
AM), -Phenyl-1, N2-etheno-8-bromoguanosine-3',5'-cy-
clic monophosphorothioate, Sp and Rp isomers (Sp- and
Rp-8-Br-PET-cGMPS) were from Biolog (Bremen, Germa-
ny). The Live/Dead Viability/Cytotoxicity Kit was from
Molecular Probes Europe (Leiden, The Netherlands). Taq-
Man Reverse Transcription reagents, SYBR Green PCR
Core reagents kit, MicroAmp Optical 96-well reaction
plates and MicroAmp optical caps were from Applied Bio-
systems (Foster City, CA, USA). The QuantumRNA™ 18S
internal standard (relative RT-PCR) was obtained from
Ambion (Austin, Texas, USA).
Methods
Isolation and culture of bovine adrenal chromaffin cells
Cells were obtained after digestion of bovine adrenal
glands with collagenase (EC 3.4.24.3) in retrograde per-
fusion as previously described [45]. After suspending in
DMEM containing: 10% heat-inactivated fetal calf serum,
standard antibiotics, 10 mol/L cytosine arabinofurano-
side and 10 mol/L fluorodeoxyuridine, the purified
chromaffin cells were plated onto collagen-treated 24-
well Costar cluster dishes at a density of 106 cells/well,
onto 6-well Costar cluster dishes at a density of 5  106
cell/well or onto white 96-well plate (Porvair) at a density
of 2  105 cell/well. Cultures were maintained at 37C in
5% CO2/95% air and used during the 3–5 days following
cell isolation. The required DETA/NO concentration was
added to the culture medium for different time periods.
When the time of treatment exceeded 24 hours, DETA/NO
was added every 24 hours.
Intracellular cyclic GMP determination
Before cGMP determination, the chromaffin cells were se-
rum-deprived for 24 hours and washed twice in Locke's
solution, pH 7.4 (composition in mmol/L: 140 NaCl, 4.4
KCl, 2.5 CaCl2, 1.2 MgSO4, 1.2 KH2PO4, 4 NaHCO3, 5.6
glucose, 0.01 EDTA and 10 HEPES). After 30-min of pre-
incubation at 37C in Locke's solution containing 0.5
mmol/L IBMX, the cells were stimulated for 10 min with
1 mol/L DEA/NO or its vehicle freshly prepared in 0.5
mL of Locke's solution. The cyclic GMP content of the
crude extracts was determined using a commercial [3H]-
cyclic GMP radioimmunoassay kit (Amersham) as de-
scribed elsewhere [48]. Experiments were performed in
triplicate. The cGMP concentration results are expressed as
pmol/106 cells  standard error respectively.
Cell viability
Cells subjected to the different treatments were washed in
Locke's solution and incubated in medium containing the
viability/cytotoxicity probes, calcein-AM 1 mol/L and
ethidium homodimer (EthD-1) 8 mol/L for 30 min at
37C as previously described [49]. Cell images were taken
with a Slow Scan Cool CCD Chamera Hammamatsu
4880–80 joined to a Nikon Eclipse TE 200 microscope,
using the B-2A FITC filter for calcein and the G-1B TRITC
filter for EthD-1.
In order to determine the relative numbers of live and
dead cells after different treatment cells were plated in 96-
well plates. Fluorescence was read in microplate reader
coupled to a Perkin-Elmer LS-50C fluorimeter. Fluores-
cence in cell sample labeled with calcein AM and EthD-1
was read at 645 nm (F(645)sam) and 530 nm (F(530)sam).
Fluorescence at 645 nm was read in a sample were all the
cells were dead and labeled either with EthD-1 only
F(645)max or with calceine AM only F(645)min. Cells were
killed by 30 min treatment with 70% methanol. Fluores-
cence at 530 nm was read in a sample were all (or nearly
all) cells were alive and labeled either with EthD-1 only
F(530)min or with calcein AM only F(530)max. The per-
centage of live cells can be calculated as: % Live cells =
(F(530)sam - F(530)min/F(530)max - F(530)min)  100, an
the percentage of dead cells can be calculated from: %
Dead cells = (F(645)sam - F(645)min/F(645)max -
F(645)min)  100.
sGC subunit protein levels
Chromaffin cells subjected to the different treatments
were processed at the required times as follows: cells wereBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/26
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washed twice in Locke's solution and disrupted in lysis
buffer containing protease inhibitors as previously de-
scribed [29]. Supernatants containing 30 g of protein
and molecular weight protein standards (precision
prestained protein standards from BIO RAD) were sub-
jected to 7.5% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and electrophoretically transferred to
PVDF membranes. After blocking non-specific binding
sites with 5% nonfat dry milk in PBS containing 0.1%
Tween-20 at room temperature for 1 hour, the mem-
branes were incubated with anti-soluble guanylyl cyclase
at 1 g/mL or anti--actin (1:1000) in blocking buffer
overnight at 4C, with constant agitation. Once washed (3
 10 min), the blots were incubated with anti-rabbit-
IgG:HRP (1:5000) and developed with the Super Signal
substrate (Pierce). Light was directly detected using Bio-
Rad Fluor S equipment. Data from western blot were ana-
lyzed using the Quantity One software (Bio-Rad).
mRNA levels quantification
The mRNA levels of both sGC subunits (1 and 1) were
determined by the quantitative RT-PCR technique.
RNA isolation
After subjecting the chromaffin cells to the different treat-
ments, total RNA was extracted using the RNeasy Kit (Qui-
agen). This method is based on the selective binding of
RNA molecules longer than 200 bases to a silica-gel mem-
brane. Biological samples are first lysed and homogenized
in the presence of a highly denaturing guanidine isothio-
cyanate (GITC)-containing buffer, which immediately in-
activates RNases to ensure isolation of intact RNA. The
RNeasy procedure isolates all RNA molecules longer than
200 nucleotides.
RNA quantification
RNA was quantified using the RiboGreen™ RNA Quantifi-
cation Kit (Molecular Probes) based on an ultra sensitive
fluorescent nucleic acid stain. The excitation maximum
for RiboGreen reagent bound to RNA is 500 nm and the
emission maximum is 525 nm. RNA was determined
from the standard curve generated by increasing amounts
of purified RNA (range 20 ng/mL to 1 g/mL). Fluores-
cence was measured using a microplate reader coupled to
a Perkin-Elmer LS-50C fluorimeter.
RT-PCR reactions
The RT-PCR reactions were performed in two-steps. First,
the first strand cDNA was synthesized with the Multi-
Scribe™ Reverse Transcriptase in RT buffer containing 5.5
mmol/L MgCl2, 500 mol/L per dNTP, 2.5 mol/L Ran-
dom Hexamers, 0.4 U/L RNase inhibitor and 3.125 U/L
MultiScribe Reverse Transcriptase. Reactions were per-
formed in a final volume of 25 L containing 1 g RNA
with an incubation step of 10 min at 25C to maximize
primer-RNA template binding. The reverse transcription
reaction was performed at 48C for 30 min and reverse
transcriptase was inactivated by heating the samples at
95C for 5 min before the PCR reactions. Specific primers
for both subunits of bovine sGC were designed using pub-
lished sequences [12,14](12, 14) with the help of the
primer express software package (Applied Biosystems).
These primers were: sGC 1-subunit (forward, base posi-
tion 526 5'-TTTGCAAACTGATTTTCCCA-3', and reverse,
base position 876 5'-TATCCAGGCATAGGATGGATG-3'),
1-subunit (forward, base position 1221 5'-ACGTTAC-
GAGCCCTGGAAG-3' and reverse, base position 1671 5'-
CTACCTCCCTGTGTGGATC-3'). 18S rRNA was used as an
endogenous control. To amplify a fragment of 324 bp, a
commercial mixture of primers and competimers (in a ra-
tio 3:7) from Ambion was employed. PCR reactions were
followed in an ABI PRISM 7700 Sequence Detection Sys-
tem (Applied Biosystems) with the SYBR Green PCR rea-
gents. The reaction mixture contained SYBR Green PCR
buffer, 1.5 mmol/L MgCl2, 200 mol/L dATP, 200 mol/
L dCTP, 200 mol/L dGTP, 400 mol/L dUTP, 0.625 U
AmpliTaq Gold DNA polymerase and 300 nmol/L of each
primer for 1 and 1 subunits, and 120 nmol/L primer
and 280 nmol/L competimers for 18S rRNA. Reactions
were performed with an initial step of AmpliTaq Gold ac-
tivation at 95C for 10 min and 40 cycles (melting phase
94C for 40 sec, annealing 60C for 30 sec and extension
68C for 45 sec). Direct monitoring of PCR products was
performed by measure the increase in fluorescence caused
by binding of SYBR Green to double-stranded DNA. The
threshold cycle or CT value occurs when the Sequence De-
tection Application begins to detect the increase in signal
associated with an exponential growth of PCR product.
Standard curves for 18S rRNA and both subunits of sGC
(1 and 1) were constructed using several dilutions of
cDNA and representing the log of the dilution versus CT
in a semilogarithmic plot. The CT values for the different
samples obtained in triplicate were interpolated in the
corresponding plot. Quantifications were always normal-
ized with the endogenous control 18S rRNA to check for
variability in the initial concentration, the quality of total
RNA and the conversion efficiency of the reverse transcrip-
tion reaction. Data from the PCR experiments were ana-
lyzed using Applied Biosystems software.
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